Over 65? How Dual Therapy Can Still Fight Hepatitis C
"Don't let age be a barrier: Discover how dual therapy effectively combats Hepatitis C genotype 2, even with an ALT flare."
Hepatitis C virus (HCV) can manifest differently, with varied biochemical and virological patterns. For those with genotype 2 chronic hepatitis C (CHC G2), guidelines often recommend dual therapy—a combination of pegylated interferon plus ribavirin. This approach has shown high success rates in achieving a sustained virological response (SVR), meaning the virus remains undetectable long after treatment ends.
While the benefits of dual therapy are well-documented for younger patients, its role in older adults (over 65) experiencing an alanine aminotransferase (ALT) flare—a sudden elevation of liver enzymes—is less clear. An ALT flare can signal rapid disease progression, making effective treatment crucial.
This article explores the effectiveness of dual therapy in older patients with CHC G2 who experience ALT flares. By examining real-world cases, we'll demonstrate how this treatment can achieve excellent virological responses, even in the face of factors that typically predict poorer outcomes.
Hepatitis C Burden and Elimination Targets
The WHO’s Global hepatitis report 2026 says hepatitis C has had a 12-week antiviral treatment with a 95% cure rate since 2015. A 2025 study summary notes that chronic HCV can lead to cirrhosis and liver cancer and that oral therapies lasting 8–12 weeks have been available since 2014. The WHO established HCV elimination targets for 2030 in 2015, including treatment targets for member countries.
Current Treatment Guidance
The CDC says hepatitis C can be cured in more than 95% of cases with 8–12 weeks of well-tolerated, oral-only direct-acting antiviral (DAA) treatment, and recommends curative DAA treatment for essentially everyone with hepatitis C. The IDSA and AASLD have collaboratively developed evidence-based HCV guidance since 2013. The initial-treatment guidance covers adults with chronic HCV who have not previously received interferon, peginterferon, ribavirin, or an HCV DAA.
Dual Therapy: A Ray of Hope for Older Patients with Hepatitis C
Italian researchers presented two compelling case studies that highlight the potential of dual therapy in older individuals with CHC G2 and ALT flares. The patients, a 69-year-old woman and a 65-year-old man, both presented with elevated liver enzymes and other risk factors.
- Rapid Virological Response (RVR): Both patients achieved undetectable HCV-RNA levels within the first four weeks of treatment.
- Complete Early Virological Response (CEVR): HCV-RNA remained undetectable at week 12.
- End-of-Treatment Response (EOT): The virus was still undetectable at the end of the 24-week treatment course.
- Sustained Virological Response (SVR): Most importantly, both patients maintained undetectable HCV-RNA levels 24 weeks after completing treatment, indicating a successful and lasting response.
Research Priorities and Treatment Developments
Nature Reviews Gastroenterology & Hepatology highlights inequitable access to testing and treatment, and barriers to viral hepatitis elimination, as priorities with five years remaining until the WHO’s 2030 goal. A 2025 review, “Hepatitis C: current treatments, emerging therapies and ...,” examines current protocols, emerging clinical-trial data, and future directions, including pursuit of a preventative vaccine. An earlier review reports that HCV treatment shifted from interferon-based to interferon-free therapy, with improvements in sustained virological response rates, safety, and tolerability, alongside shorter treatment duration.
When DAA Treatment Fails
A review reports initial DAA cure rates of 95%–99% and retreatment cure rates of 95%, while noting that some people ultimately experience multiple DAA failures. A 2022 review says pan-genotypic regimens are recommended as first-line and rescue treatments for chronic HCV. If a pan-genotypic regimen is unavailable, it describes retreatment principles that include using different DAA classes, extending treatment duration, adding ribavirin (RBV), and testing for HCV resistance-associated substitutions (RASs).
Regimens and Comparison Criteria
The Lancet source says the WHO recommends treating hepatitis C with one of three antiviral combinations for 8–12 weeks. A comparison article specifically names Copegus (ribavirin) and modern hepatitis C antivirals, and says it covers efficacy, side effects, cost, and when each option makes sense; the supplied summary does not give comparative results. Healthline reports that advances in hepatitis C treatment mean most people can now be cured, while up to 50% may clear HCV without treatment and the infection becomes chronic for everyone else.
What This Means for You
If you're over 65 and have hepatitis C genotype 2, an ALT flare doesn't automatically disqualify you from effective treatment. These cases demonstrate that dual therapy can still be a viable option, leading to sustained viral response and improved liver health.
Global Burden and Treatment Access
A 2024 MDPI review reports that approximately 50 million people were living with chronic hepatitis C worldwide, based on the WHO, and describes HCV as a significant global health challenge. The review says HCV contributes extensively to global morbidity and mortality. It also reports that the approval of several direct-acting antiviral regimens significantly improved HCV treatment, offering potentially high rates of success.
Talk to your doctor about whether dual therapy is right for you. They can assess your individual risk factors and determine the best course of action.
Even with new drugs emerging, these findings highlight the continued importance of dual therapy in specific patient populations. Don't let age or ALT flares stand in the way of exploring your treatment options and achieving a healthier future.